Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fusion Pharmaceuticals Inc FUSN

Healthcare Biotechnology
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by... see more

Recent & Breaking News (NDAQ:FUSN)

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire July 6, 2023

Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

PR Newswire June 26, 2023

Fusion Pharmaceuticals to Present at the TD Cowen Radiopharmaceutical Innovation Summit

PR Newswire June 16, 2023

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Canada NewsWire June 7, 2023

Fusion Pharmaceuticals to Present at the Jefferies Healthcare Conference

PR Newswire May 31, 2023

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates

PR Newswire May 11, 2023

Fusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

PR Newswire May 9, 2023

Fusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer

PR Newswire May 2, 2023

Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

PR Newswire April 20, 2023

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2059 and Leading Targeted Alpha Therapy Platform at AACR Annual Meeting

PR Newswire April 19, 2023

Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy

PR Newswire April 12, 2023

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire April 5, 2023

Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1

PR Newswire March 20, 2023

Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates

PR Newswire March 16, 2023

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire March 8, 2023

Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference

PR Newswire March 2, 2023

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer

PR Newswire February 13, 2023

Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

PR Newswire February 13, 2023

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire February 7, 2023

Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights

PR Newswire January 6, 2023